Emergent BiosolutionsEBS
EBS
About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Employees: 900
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
3% more funds holding
Funds holding: 156 [Q4 2024] → 160 (+4) [Q1 2025]
2.48% more ownership
Funds ownership: 64.13% [Q4 2024] → 66.6% (+2.48%) [Q1 2025]
1% less call options, than puts
Call options by funds: $944K | Put options by funds: $956K
47% less capital invested
Capital invested by funds: $332M [Q4 2024] → $176M (-$156M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$15
140%
upside
Avg. target
$15
140%
upside
High target
$15
140%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 140%upside $15 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 3 articles about EBS published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple light bulb (Shine), a wearable promotional item (Wear), a QR code encouraging participation in the #sharenaloxone social media campaign (Share) and a box of NARCAN® Nasal Spray (Care) provided by Emergent.
Positive
Zacks Investment Research
2 weeks ago
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence.
Positive
Zacks Investment Research
4 weeks ago
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns.
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York) Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via webcast Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference Presentation on Thursday, May 29 Jefferies Global Healthcare Conference (New York, New York) Presentation on Thursday, June 5 at 1:25 pm ETVirtual attendees can participate via webcast A replay of the presentations can be accessed from the Investors page of Emergent's website.
Neutral
Seeking Alpha
1 month ago
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by.
Positive
Zacks Investment Research
1 month ago
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions Reports First Quarter 2025 Financial Results
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior year First Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior year First Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior year Reaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario
Neutral
GlobeNewsWire
1 month ago
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.
Neutral
GlobeNewsWire
2 months ago
Emergent BioSolutions Announces Stock Repurchase Program
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026.
Charts implemented using Lightweight Charts™